LFST vs MRK
LifeStance Health Group, Inc. vs Merck & Co. — AI-powered side-by-side comparison
LFST
LifeStance Health Group, Inc.
53
Watch
VS
| Metric | LFST | MRK |
|---|
| AI Score |
53
|
70
|
| Price |
$11.51
|
$130.34
|
| P/E Ratio |
88.33×
|
103.53×
|
| ROE |
0.6%
|
34.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
25.8%
|
75.4%
|
| Debt / Equity |
0.14×
|
1.29×
|
| Dividend Yield |
0.0%
|
2.6%
|
| RSI (14) |
62.9
|
64.5
|
| Beta |
1.138
|
0.207
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for LFST versus MRK.
MRK leads by 17 points.
MRK scores 70/100 (Buy) versus LFST at 53/100 (Watch).
LFST Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -12.8% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- P/E of 196.0 is expensive by classic value standards — Value
- ROE of only 1.6% -- cheap may mean cheap for a reason — Value
- Revenue declining -12.8% YoY -- this is not a growth story right now — Growth
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical